HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Di(2-ethylhexyl) phthalate monograph will be released in October by National Toxicology Program's Center for the Evaluation of Risks to Human Reproduction, agency reports during Board of Scientific Counselors Meeting Sept. 10-11 in Research Triangle Park, N.C. NTP released a monograph on di-n-butyl phthalate in March (1"The Rose Sheet" March 24, 2003, p. 6). Agency also unveiled its draft vision for the toxicology program, which advocates shifting basis for decision-making to rely on faster, mechanism-based assays rather than empirical tests. NTP anticipates developing more specific draft principles, roadmap of goals to be accomplished under new strategy by July 2004...

You may also be interested in...

Di-N-Butyl Phthalate Monograph Released By NTP

The National Toxicology Program has "some concern" di-n-butyl phthalate causes adverse effects to human development, particularly development of the reproductive system, according to a monograph released by NTP's Center for the Evaluation of Risks to Human Reproduction in a 1March 18 Federal Register notice

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts